Table 1

QCT analysis of the proximal tibia metaphysis from ovariectomized rats treated with LY353381.HC1

Groups	BMD	BMC	X-Area
	mg/ml	mg	mm²
Sham	719 ± 32^o	18.7 ± 0.5^o	21.8 ± 0.7
OVX	561 ± 19^s	15.5 ± 0.6^s	23.1 ± 0.6
0.0001 mg/kg	624 ± 21^o,s	15.3 ± 0.7^s	20.4 ± 0.5
0.001 mg/kg	606 ± 18^s	16.6 ± 0.6^s	22.8 ± 0.7
0.01 mg/kg	660 ± 7^o,s	17.3 ± 0.4	21.9 ± 0.5
0.1 mg/kg	724 ± 20^o	18.5 ± 1^o	21.3 ± 0.8
1.0 mg/kg	652 ± 12^o,s	17.9 ± 0.7^o	23 ± 1.1
10 mg/kg	744 ± 25^o	17.7 ± 0.7^o	19.9 ± 0.5^o
EE2 0.1 mg/kg	699 ± 19^o	17.6 ± 0.6^o	21 ± 0.5^o
RA 1 mg/kg	706 ± 25^o	17.8 ± 0.6^o	21.1 ± 0.8
ANOVA	<.0001	.0036	.0449

Prevention model (experiment 1): Rats were ovariectomized (except for Sham) and orally treated for 5 weeks with vehicle (Ovx), 0.0001–10 mg/kg/day LY353381.HC1, 0.1 mg/kg/day 17α ethynyl estradiol (EE2), or 1 mg/kg/day raloxifene (RA), as indicated. QCT was used to analyze the volumetric bone mineral density (BMD, mg/cc), bone mineral content (BMC, mg), and cross-sectional area (X-Area, mm2) for the proximal tibia metaphysis. Data are mean ± S.E.M. for n = 6–7 for each group. Comparisons were made to Sham and OVX controls; significant differences (P < .05) from Ovx are designated “o”, while significant differences from Sham are designated “s” (Fisher’s PLSD). Dose-dependent effects of LY353381.HC1 were observed for the BMD and BMC with half-maximal efficacy of about ED₅₀ = 0.01 mg/kg.